ASA Monitor May 2024, Vol. 88, 27. A 16-week clinical trial conducted by the National Institutes of Health (NIH) showcased promising results for the monoclonal antibody, omalizumab, in reducing allergic reactions to multiple foods among children ages 1 year and older with food allergies. The trial revealed that nearly 67% of participants who underwent omalizumab treatment […]
Read MoreAuthors: Christopher Fadumiye, MD, FASA et al ASA Monitor June 2024, Vol. 88, 30. Implementation of curricula is constantly evolving, supporting improvements in the quality of medical education and clinical practice (Eur J Anaesthesiol 2019;36:473-6). Evolution within medical education in anesthesiology reflects many factors, including changes in the health care environment and the role of the physician, […]
Read MoreAuthors: Debnath Chatterjee, MD, FAAP, FASA; Viviane Nasr, MD, MPH, FASA ASA Monitor May 2024, Vol. 88, 22–23. Perioperative risk stratification is an integral part of informed consent and medical decision-making processes. It also guides resource allocation and appropriate escalation of care, such as transfer to intensive care settings or tertiary-care hospitals. Fortunately, the incidence of perioperative […]
Read MoreAuthors: Douglas A. Colquhoun, M.B.Ch.B., M.Sc., M.P.H. et al Anesthesiology Newly Published on April 2024. “Despite these limitations, this study still calls attention to the importance of preserving access to routine propofol use in patients undergoing screening and surveillance colonoscopy.” In this month’s issue of the Journal, Quaye et al. report findings of their investigation into […]
Read MoreAuthors: Mohamed A. Ibrahim, MD, PhD, MBA, FASA; Pamela Flood, MD, MA ASA Monitor May 2024, Vol. 88, 20–21. This edition of the ASA Monitor is focused on 30-day postoperative mortality. A search for “30-day mortality” and “obstetrics” on PubMed returns no results! Perhaps women don’t die after labor and delivery. However, the publication of more than 52,000 articles […]
Read More